These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25526229)

  • 21. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.
    Wang Y; Cipriano A; Munera C; Harris SC
    J Clin Pharmacol; 2016 Oct; 56(10):1263-71. PubMed ID: 26865472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase.
    Gordon A; Callaghan D; Spink D; Cloutier C; Dzongowski P; O'Mahony W; Sinclair D; Rashiq S; Buckley N; Cohen G; Kim J; Boulanger A; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC; Michalko KJ
    Clin Ther; 2010 May; 32(5):844-60. PubMed ID: 20685494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of buprenorphine transdermal system in the management of pain in older adults.
    Pergolizzi JV; Raffa RB; Marcum Z; Colucci S; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):92-101. PubMed ID: 27929709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system.
    Silverman S; Raffa RB; Cataldo MJ; Kwarcinski M; Ripa SR
    J Pain Res; 2017; 10():1255-1263. PubMed ID: 28579823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
    Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
    Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.
    Mitra F; Chowdhury S; Shelley M; Williams G
    Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
    Plosker GL
    Drugs; 2011 Dec; 71(18):2491-509. PubMed ID: 22141389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis.
    Munera C; Drehobl M; Sessler NE; Landau C
    J Opioid Manag; 2010; 6(3):193-202. PubMed ID: 20642248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.
    Weil AJ; Masters ET; Barsdorf AI; Bass A; Pixton G; Wilson JG; Wolfram G
    Health Qual Life Outcomes; 2017 Oct; 15(1):202. PubMed ID: 29041942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
    Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
    J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain.
    Zah V; Stanicic F; Vukicevic D; Grbic D
    Pain Manag; 2024; 14(4):195-207. PubMed ID: 38939964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Transdermal Buprenorphine versus Oral Tramadol/Acetaminophen in Patients with Persistent Postoperative Pain after Spinal Surgery.
    Lee JH; Kim JH; Kim JH; Kim HS; Min WK; Park YS; Lee KY; Lee JH
    Pain Res Manag; 2017; 2017():2071494. PubMed ID: 29056859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.
    Coplan PM; Sessler NE; Harikrishnan V; Singh R; Perkel C
    Postgrad Med; 2017 Jan; 129(1):55-61. PubMed ID: 27922764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain.
    James IG; O'Brien CM; McDonald CJ
    J Pain Symptom Manage; 2010 Aug; 40(2):266-78. PubMed ID: 20541900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
    Likar R; Kayser H; Sittl R
    Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.